Clinical trial
An Open-Label Multiple-Dose Study of RZ358 in Patients With Congenital Hyperinsulinism
NCT04538989 is registered in ClinicalTrials.gov with Rezolute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label Multiple-Dose Study of RZ358 in Patients With Congenital Hyperinsulinism
- Lead sponsor
- Rezolute
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- February 24, 2020
- Completion date
- August 19, 2022
- Enrollment
- 23 (actual)
- Sites
- 17
Conditions
As the registry lists them; a condition with its own page is linked.